US Stock MarketDetailed Quotes

TCRX TScan Therapeutics

Watchlist
  • 2.100
  • +0.080+3.96%
Close Feb 28 16:00 ET
  • 2.100
  • 0.0000.00%
Post 20:01 ET
118.66MMarket Cap-2.21P/E (TTM)

About TScan Therapeutics Company

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Company Profile

SymbolTCRX
Company NameTScan Therapeutics
Listing DateJul 16, 2021
Issue Price15.00
Founded2018
CEODr. Gavin MacBeath, PhD
MarketNASDAQ
Employees154
Fiscal Year Ends12-31
Address830 Winter Street
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451
Phone1-857-399-9500

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Gavin MacBeath, PhD
  • Chief Executive Officer and Director
  • 3.20M
  • Dr. Zoran Zdraveski
  • Chief Legal and Strategy Officer and Secretary
  • 1.58M
  • Jason A. Amello
  • Treasurer, Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Chrystal U. Louis, M.D.
  • Chief Medical Officer
  • --
  • Leiden Dworak
  • Vice President, Finance
  • --
  • Dr. Stephen R. Biggar,M.D.,PhD
  • Chairman of the Board
  • 123.17K
  • Garry A. Nicholson
  • Independent Director
  • --
  • Dr. Gabriela Gruia, M.D.
  • Independent Director
  • 113.53K
  • Katina Dorton, J.D.,M.B.A.
  • Independent Director
  • 132.59K
  • Robert Keith Woods
  • Independent Director
  • 90.90K
  • Dr. Barbara Klencke, M.D.
  • Independent Director
  • 121.74K
Trending Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.